<![CDATA[Biotek-snakken — September 2024]]>Godmorgen...

]]>https://dev.proinvestor.com/forum/topic/401447/biotek-snakken-september-2024RSS for NodeSat, 06 Jun 2026 04:41:02 GMTSun, 01 Sep 2024 03:24:51 GMT60<![CDATA[Reply to Biotek-snakken — September 2024 on Sun, 29 Sep 2024 11:08:36 GMT]]>I
s Viking Therapeutics Stock a Buy? https://proinvestor.com/investornyt/1220185/is-viking-therapeutics-stock-a-buy

]]>https://dev.proinvestor.com/forum/post/8067764https://dev.proinvestor.com/forum/post/8067764Sun, 29 Sep 2024 11:08:36 GMT<![CDATA[Reply to Biotek-snakken — September 2024 on Sun, 29 Sep 2024 03:04:35 GMT]]>Enliven Therapeutics Updates Positive Phase 1 Data For ELVN-001 In Chronic Myeloid Leukemia Patients https://proinvestor.com/investornyt/1220121/enliven-therapeutics-updates-positive-phase-1-data-for-elvn-001-in-chronic-myeloid-leukemia-patients

]]>https://dev.proinvestor.com/forum/post/8067766https://dev.proinvestor.com/forum/post/8067766Sun, 29 Sep 2024 03:04:35 GMT<![CDATA[Reply to Biotek-snakken — September 2024 on Fri, 27 Sep 2024 11:56:40 GMT]]>Lundbeck vil forstå kronisk nervesygdom bedre med nyt studie https://proinvestor.com/investornyt/1219563/lundbeck-vil-forsta-kronisk-nervesygdom-bedre-med-nyt-studie

]]>https://dev.proinvestor.com/forum/post/8067762https://dev.proinvestor.com/forum/post/8067762Fri, 27 Sep 2024 11:56:40 GMT<![CDATA[Reply to Biotek-snakken — September 2024 on Fri, 27 Sep 2024 03:20:27 GMT]]>FDA panel votes against PD-1s in gastric, oesophageal cancers with low biomarker expression https://firstwordpharma.com/story/5899318

]]>https://dev.proinvestor.com/forum/post/8067759https://dev.proinvestor.com/forum/post/8067759Fri, 27 Sep 2024 03:20:27 GMT<![CDATA[Reply to Biotek-snakken — September 2024 on Fri, 27 Sep 2024 03:19:22 GMT]]>AstraZeneca scores wider US lung cancer label for Tagrisso https://firstwordpharma.com/story/5899045

]]>https://dev.proinvestor.com/forum/post/8067758https://dev.proinvestor.com/forum/post/8067758Fri, 27 Sep 2024 03:19:22 GMT<![CDATA[Reply to Biotek-snakken — September 2024 on Fri, 27 Sep 2024 03:18:30 GMT]]>AbbVie sets sights on clinical hat trick for Cerevel Parkinson's drug https://firstwordpharma.com/story/5899132

]]>https://dev.proinvestor.com/forum/post/8067756https://dev.proinvestor.com/forum/post/8067756Fri, 27 Sep 2024 03:18:30 GMT<![CDATA[Reply to Biotek-snakken — September 2024 on Fri, 27 Sep 2024 02:42:00 GMT]]>SEC Announces $40 Mln Settlement With Cassava Sciences Over Misleading Alzheimer's Trial Statements https://proinvestor.com/investornyt/1219394/sec-announces-40-mln-settlement-with-cassava-sciences-over-misleading-alzheimers-trial-statements

]]>https://dev.proinvestor.com/forum/post/8067763https://dev.proinvestor.com/forum/post/8067763Fri, 27 Sep 2024 02:42:00 GMT<![CDATA[Reply to Biotek-snakken — September 2024 on Fri, 27 Sep 2024 02:33:19 GMT]]>Evaxion sælger rettigheder til to vaccinekandidater for potentielt milliardbeløb
Det er partneren MSD, som køber retten til en vaccinekandidat mod gonoré og et ikke-offentliggjort infektionsmiddel. (Medwatch abonnement) https://medwatch.dk/Medicinal___Biotek/article17484915.ece?utm_campaign=MedWatch Topnyhed&utm_content=2024-09-26&utm_medium=email&utm_source=medwatch

]]>https://dev.proinvestor.com/forum/post/8067757https://dev.proinvestor.com/forum/post/8067757Fri, 27 Sep 2024 02:33:19 GMT<![CDATA[Reply to Biotek-snakken — September 2024 on Fri, 27 Sep 2024 02:32:02 GMT]]>Evaxion significantly expands vaccine development collaboration with MSD https://investors.evaxion-biotech.com/news-releases/news-release-details/evaxion-significantly-expands-vaccine-development-collaboration

]]>https://dev.proinvestor.com/forum/post/8067753https://dev.proinvestor.com/forum/post/8067753Fri, 27 Sep 2024 02:32:02 GMT<![CDATA[Reply to Biotek-snakken — September 2024 on Fri, 27 Sep 2024 02:19:30 GMT]]>Bristol Myers Squibb's COBENFY Gains FDA Approval For Adult Schizophrenia Treatment https://proinvestor.com/investornyt/1219377/bristol-myers-squibbs-cobenfy-gains-fda-approval-for-adult-schizophrenia-treatment

]]>https://dev.proinvestor.com/forum/post/8067765https://dev.proinvestor.com/forum/post/8067765Fri, 27 Sep 2024 02:19:30 GMT<![CDATA[Reply to Biotek-snakken — September 2024 on Fri, 27 Sep 2024 02:18:18 GMT]]>Biomea Fusion : FDA Lifts Clinical Hold On BMF-219 For Type 1 And Type 2 Diabetes Trials; Stock Up https://proinvestor.com/investornyt/1219387/biomea-fusion-fda-lifts-clinical-hold-on-bmf-219-for-type-1-and-type-2-diabetes-trials-stock-up

]]>https://dev.proinvestor.com/forum/post/8067751https://dev.proinvestor.com/forum/post/8067751Fri, 27 Sep 2024 02:18:18 GMT<![CDATA[Reply to Biotek-snakken — September 2024 on Fri, 27 Sep 2024 02:17:32 GMT]]>Travere Therapeutics Pauses Enrollment In Phase 3 Study Of Pegtibatinase For Manufacturing Scale-Up https://proinvestor.com/investornyt/1219391/travere-therapeutics-pauses-enrollment-in-phase-3-study-of-pegtibatinase-for-manufacturing-scale-up

]]>https://dev.proinvestor.com/forum/post/8067754https://dev.proinvestor.com/forum/post/8067754Fri, 27 Sep 2024 02:17:32 GMT<![CDATA[Reply to Biotek-snakken — September 2024 on Fri, 27 Sep 2024 01:36:46 GMT]]>Godmorgen...

]]>https://dev.proinvestor.com/forum/post/8067752https://dev.proinvestor.com/forum/post/8067752Fri, 27 Sep 2024 01:36:46 GMT<![CDATA[Reply to Biotek-snakken — September 2024 on Wed, 25 Sep 2024 04:20:38 GMT]]>SEB inleder bevakning på Genovis med köp och riktkurs 30 kronor - BN /Finwire

]]>https://dev.proinvestor.com/forum/post/8067755https://dev.proinvestor.com/forum/post/8067755Wed, 25 Sep 2024 04:20:38 GMT<![CDATA[Reply to Biotek-snakken — September 2024 on Mon, 23 Sep 2024 11:30:31 GMT]]>Genovis Launches FabRICATOR® Xtra: Next-Generation Enzyme for Future Antibody Therapeutics

https://news.cision.com/genovis-ab/r/genovis-launches-fabricator--xtra--next-generation-enzyme-for-future-antibody-therapeutics,c4041294

]]>https://dev.proinvestor.com/forum/post/8067761https://dev.proinvestor.com/forum/post/8067761Mon, 23 Sep 2024 11:30:31 GMT<![CDATA[Reply to Biotek-snakken — September 2024 on Mon, 23 Sep 2024 03:18:02 GMT]]>Sanofi gears up to seek approval of BTK inhibitor tolebrutinib in MS https://firstwordpharma.com/story/5897608

]]>https://dev.proinvestor.com/forum/post/8067750https://dev.proinvestor.com/forum/post/8067750Mon, 23 Sep 2024 03:18:02 GMT<![CDATA[Reply to Biotek-snakken — September 2024 on Mon, 23 Sep 2024 03:16:20 GMT]]>FDA greenlights Sanofi's Sarclisa in frontline multiple myeloma https://firstwordpharma.com/story/5897967

]]>https://dev.proinvestor.com/forum/post/8067745https://dev.proinvestor.com/forum/post/8067745Mon, 23 Sep 2024 03:16:20 GMT<![CDATA[Reply to Biotek-snakken — September 2024 on Mon, 23 Sep 2024 01:28:06 GMT]]>Godmorgen...

]]>https://dev.proinvestor.com/forum/post/8067760https://dev.proinvestor.com/forum/post/8067760Mon, 23 Sep 2024 01:28:06 GMT<![CDATA[Reply to Biotek-snakken — September 2024 on Sat, 21 Sep 2024 04:25:13 GMT]]>FDA Approves Zevra Therapeutics' MIPLYFFA For Treatment Of Niemann-Pick Disease Type C https://proinvestor.com/investornyt/1216783/fda-approves-zevra-therapeutics-miplyffa-for-treatment-of-niemann-pick-disease-type-c

]]>https://dev.proinvestor.com/forum/post/8067749https://dev.proinvestor.com/forum/post/8067749Sat, 21 Sep 2024 04:25:13 GMT<![CDATA[Reply to Biotek-snakken — September 2024 on Sat, 21 Sep 2024 01:32:48 GMT]]>Godmorgen...

]]>https://dev.proinvestor.com/forum/post/8067748https://dev.proinvestor.com/forum/post/8067748Sat, 21 Sep 2024 01:32:48 GMT<![CDATA[Reply to Biotek-snakken — September 2024 on Fri, 20 Sep 2024 02:01:29 GMT]]>Ascendis Pharma Prices Public Offering Of 2 Mln ADSs At $150.00/ADS https://proinvestor.com/investornyt/1216242/ascendis-pharma-prices-public-offering-of-2-mln-adss-at-15000-ads

]]>https://dev.proinvestor.com/forum/post/8067744https://dev.proinvestor.com/forum/post/8067744Fri, 20 Sep 2024 02:01:29 GMT<![CDATA[Reply to Biotek-snakken — September 2024 on Fri, 20 Sep 2024 02:00:55 GMT]]>Tectonic Therapeutics Announces Positive Phase 1a Results For TX45 In Treating Group 2 PH-HFpEF https://proinvestor.com/investornyt/1216248/tectonic-therapeutics-announces-positive-phase-1a-results-for-tx45-in-treating-group-2-ph-hfpef

]]>https://dev.proinvestor.com/forum/post/8067743https://dev.proinvestor.com/forum/post/8067743Fri, 20 Sep 2024 02:00:55 GMT<![CDATA[Reply to Biotek-snakken — September 2024 on Fri, 20 Sep 2024 02:00:06 GMT]]>ELAN : FDA Oks Zenrelia, Once-Daily Oral JAK Inhibitor For Dogs With Allergic And Atopic Dermatitis https://proinvestor.com/investornyt/1216251/elan-fda-oks-zenrelia-once-daily-oral-jak-inhibitor-for-dogs-with-allergic-and-atopic-dermatitis

]]>https://dev.proinvestor.com/forum/post/8067741https://dev.proinvestor.com/forum/post/8067741Fri, 20 Sep 2024 02:00:06 GMT<![CDATA[Reply to Biotek-snakken — September 2024 on Thu, 19 Sep 2024 14:37:02 GMT]]>https://saniona.com/newsroom/single-press-release/?slug=saniona-receives-regulatory-approval-for-san711-biomarker-study Saniona Receives Regulatory Approval for SAN711 Biomarker Study

]]>https://dev.proinvestor.com/forum/post/8067742https://dev.proinvestor.com/forum/post/8067742Thu, 19 Sep 2024 14:37:02 GMT